Clinical trial · no report yet · Phase 1
NCT05680922
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
- NCT05680922 ↗
- Active, not recruiting
- Legend Biotech USA Inc
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Small Cell Lung Cancer Extensive Stage; Large Cell Neuroendocrine Carcinoma of the Lung
- Interventions
- LB2102
- Arms
- Experimental LB2102 · Experimental
- Enrollment
- 41 (estimated)
- Primary outcomes
- To characterize the safety and tolerability of LB2102 and determine recommended dose for expansion (RDE)
- To further characterize the safety and tolerability of LB2102 with the RDE identified in the dose-escalation and determine the recommended Phase 2 dose (RP2D)
- Sponsor
- Legend Biotech USA Inc
- Start
- Jul 26, 2023
- Primary completion
- Dec 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05680922 · updated Mar 24, 2026
Publications
linked from the registry- Williams CM, Arnold SM, Villano JL, Alonso ENA, Brainson CF, Schwarzenberger PO, Vahora S, Qasrawi A, Munker R, Evers BM, Hao Z. Safety and efficacy of DLL3 CAR-T cells armored with dnTGFBR2 in a subject with recurrent small-cell lung cancer: case report. Front Oncol. 2026 Jul 7;16:1885732. doi: 10.3389/fonc.2026.1885732. eCollection 2026. PubMed 42482749
- Ouyang W, Xu Z, Guan S, Hu Y, Gou X, Liu Z, Guo W, Huang Y, Zhang L, Zhang X, Li T, Yang B. Advancement Opportunities and Endeavor of Innovative Targeted Therapies for Small Cell Lung Cancer. Int J Biol Sci. 2025 Jan 20;21(3):1322-1341. doi: 10.7150/ijbs.105973. eCollection 2025. PubMed 39897044